A retrospective study revealed famotidine is associated with improved clinical outcomes for patients hospitalized with COVID-19.

Key Messages

This retrospective study, carried out in New York, examined the disease progression in 1,620 hospitalized COVID-19 patients, 84 of whom were given famotidine within 24 hours of being admitted to hospital.

All patients who were given famotidine were included in the famotidine group regardless of any differences in the dose, method of administration and the length of time they received it.

Overall, patients were given relatively low doses of the famotidine for short time periods. The median dose was 136 mg over a median 5.8 days (i.e. an average of 23.5 mg per day).

The analysis revealed that in hospitalized Covid-19 patients who were not initially ventilated, famotidine treatment led to a 2-fold reduction in severe clinical deterioration leading to a need for ventilation or death.
Famotidine users were treated with relatively small doses of the drug. The total median dose of 136 mg was related to 5.8 days of median time of famotidine administration.

The analysis revealed that in hospitalized, not initially intubated COVID-19 patients, famotidine use is related to a 2-fold reduction in clinical deterioration leading to intubation or death.

Authors stress that randomized controlled trials are necessary to confirm findings.

Gastroenterology

Publication Date: May 22, 2020
Peer Reviewed: Yes
Publication Type: Original | Clinical Retrospective
DOI: https://www.doi.org/10.1053/j.gastro.2020.05.053

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Daniel E. Freedberg, Joseph Conigliaro, Timothy C. Wang, Kevin J. Tracey, Michael V. Callahan, Julian A. Abrams, Magdalena E. Sobieszczyk, David D. Markowitz, Aakriti Gupta, Max R. O’Donnell, Jianhua Li, David A. Tuveson, Zhezhen Jin, William C. Turner, Donald W. Landry